G Lübben

2.0k total citations
40 papers, 1.6k citations indexed

About

G Lübben is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Epidemiology. According to data from OpenAlex, G Lübben has authored 40 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Endocrinology, Diabetes and Metabolism, 16 papers in Molecular Biology and 12 papers in Epidemiology. Recurrent topics in G Lübben's work include Diabetes Treatment and Management (16 papers), Metabolism, Diabetes, and Cancer (13 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (10 papers). G Lübben is often cited by papers focused on Diabetes Treatment and Management (16 papers), Metabolism, Diabetes, and Cancer (13 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (10 papers). G Lübben collaborates with scholars based in Germany, Japan and Switzerland. G Lübben's co-authors include Thomas Först, Andreas Pfützner, Thomas R. Konrad, C Hohberg, Matthias Langenfeld, Nikolaus Marx, M Hanefeld, Peter Herbert Kann, Daniel Walcher and Efstrathios Karagiannis and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

G Lübben

38 papers receiving 1.5k citations

Peers

Countries citing papers authored by G Lübben

Since Specialization

Citations

This map shows the geographic impact of G Lübben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Lübben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Lübben more than expected).

Fields of papers citing papers by G Lübben

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G Lübben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Lübben. The network helps show where G Lübben may publish in the future.

Co-authorship network of co-authors of G Lübben

This figure shows the co-authorship network connecting the top 25 collaborators of G Lübben. A scholar is included among the top collaborators of G Lübben based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G Lübben. G Lübben is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β‐cell function: results from the PioSwitch Study 2009 ·Diabetes Obesity and Metabolism ·C Hohberg, Andreas Pfützner, Thomas Först, G Lübben, Efstratios Karagiannis, (unknown), Thomas Schöndorf	16
2	Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study 2008 ·Atherosclerosis ·W. Leonhardt, Andreas Pfützner, Jürgen Müller, Jens Pietzsch, Thomas Först, Efstrathios Karagiannis, G Lübben, M Hanefeld	14
3	Pioglitazone Improves Metabolic Markers in Patients with Type 2 Diabetes Independently from Physical Activities: Results from the IRIS III Study 2008 ·Journal of Diabetes Science and Technology ·Thomas Schöndorf, Andreas Pfützner, G Lübben, Efstrathios Karagiannis, (unknown), Thomas Först	2
4	The IRIS V Study: Pioglitazone Improves Systemic Chronic Inflammation in Patients with Type 2 Diabetes Under Daily Routine Conditions 2008 ·Diabetes Technology & Therapeutics ·Efstrathios Karagiannis, Andreas Pfützner, Thomas Först, G Lübben, (unknown), (unknown), (unknown), Thomas Schöndorf	20
5	Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein 2007 ·Journal of the American College of Cardiology ·M Hanefeld, Nikolaus Marx, Andreas Pfützner, (unknown), G Lübben, Efstrathios Karagiannis, (unknown), Thomas Först	141
6	Visfatin: A Putative Biomarker for Metabolic Syndrome is not Influenced by Pioglitazone or Simvastatin Treatment in Nondiabetic Patients at Cardiovascular Risk - Results from the PIOSTAT Study 2007 ·Hormone and Metabolic Research ·Andreas Pfützner, M Hanefeld, G Lübben, M. A. Weber, Efstratios Karagiannis, (unknown), C Hohberg, Thomas Först	28
7	Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease 2007 ·Atherosclerosis ·Thomas Först, Efstratios Karagiannis, G Lübben, C Hohberg, Thomas Schöndorf, Gerhard Dikta, (unknown), Michael Morcos, Wilfried Dänschel, (unknown), Andreas Pfützner	36
8	Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk—the PIOSTAT Study 2007 ·Metabolism ·Thomas Först, Andreas Pfützner, G Lübben, Matthias M. Weber, Nikolaus Marx, Efstrathios Karagiannis, Carsta Koehler, (unknown), C Hohberg, M Hanefeld	60
9	Review of the Pleiotropic Effects of Peroxisome Proliferator-Activated Receptor γ Agonists on Platelet Function 2007 ·Diabetes Technology & Therapeutics ·(unknown), Thomas Schöndorf, G Lübben, Thomas Först, Andreas Pfützner	13
10	Association of high-sensitive C-reactive protein with advanced stage β-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus 2006 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·Andreas Pfützner, Eberhard Standl, (unknown), Jan Schulze, C Hohberg, G Lübben, (unknown), Thomas Schöndorf, Thomas Först	23
11	Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic Control 2005 ·Journal of the American College of Cardiology ·Andreas Pfützner, Nikolaus Marx, G Lübben, Matthias Langenfeld, Daniel Walcher, Thomas R. Konrad, Thomas Först	233
12	Pharmacological PPARγ Stimulation in Contrast to Beta Cell Stimulation Results in an Improvement in Adiponectin and Proinsulin Intact Levels and Reduces Intima Media Thickness in Patients with Type 2 Diabetes 2005 ·Hormone and Metabolic Research ·Thomas Först, (unknown), (unknown), G Lübben, Thomas R. Konrad, M Löbig, Matthias M. Weber, (unknown), (unknown), Andreas Pfützner	38
13	Pioneer Study: PPARγ Activation Results in Overall Improvement of Clinical and Metabolic Markers Associated with Insulin Resistance Independent of Long-term Glucose Control 2005 ·Hormone and Metabolic Research ·Andreas Pfützner, C Hohberg, G Lübben, (unknown), (unknown), Peter Herbert Kann, Thomas Först	33
14	IRIS II Study: Intact Proinsulin Is Confirmed as a Highly Specific Indicator for Insulin Resistance in a Large Cross-Sectional Study Design 2005 ·Diabetes Technology & Therapeutics ·Andreas Pfützner, Eberhard Standl, C Hohberg, Thomas R. Konrad, (unknown), G Lübben, Matthias Langenfeld, Jan Schulze, Thomas Först	24
15	Coefficient of β-Cell Failure in Patients with Type 2 Diabetes Treated with Pioglitazone or Acarbose 2004 ·Experimental and Clinical Endocrinology & Diabetes ·Burkhard Göke, G Lübben, P. C. Bates	9
16	A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus 2004 ·Clinical Therapeutics ·Jochen Seufert, G Lübben, (unknown), P. C. Bates	50
17	IRIS II Study: Sensitivity and Specificity of Intact Proinsulin, Adiponectin, and the Proinsulin/Adiponectin Ratio as Markers for Insulin Resistance 2004 ·Diabetes Technology & Therapeutics ·Matthias Langenfeld, Thomas Först, Eberhard Standl, (unknown), G Lübben, (unknown), Peter Herbert Kann, Andreas Pfützner	11
18	Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus 2003 ·Current Medical Research and Opinion ·(unknown), G Lübben, (unknown), (unknown)	44
19	Screening for early prostate cancer in Germany. Preliminary results of a prospective multicenter trial 1999 ·Der Urologe ·(unknown), (unknown), J. E. Altwein, K.-H. Bichler, (unknown), Johannes Hüsing, Paolo Fornara, Karl‐Heinz Jöckel, G Lübben, (unknown), L. Weißbach, Manfred P. Wirth, H. Rübben	11
20	Efficacy and Safety of Leuprorelin Acetate Depot for Prostate Cancer 1996 ·Urologia Internationalis ·(unknown), G Lübben	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact